-
Something wrong with this record ?
HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix
L. Dostalek, P. Freitag, M. Slovackova, T. Zima, M. Komarc, L. Fricova, T. Fucik, K. Nemejcova, D. Cibula, D. Brynda, J. Slama
Language English Country England, Great Britain
Document type Journal Article
NLK
ProQuest Central
from 2018-01-01 to 6 months ago
Health & Medicine (ProQuest)
from 2018-01-01 to 6 months ago
- MeSH
- Adenocarcinoma virology pathology MeSH
- Adult MeSH
- Papillomavirus Infections * diagnosis virology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Uterine Cervical Neoplasms * virology pathology diagnosis therapy MeSH
- Follow-Up Studies MeSH
- Papillomaviridae isolation & purification MeSH
- Retrospective Studies MeSH
- Triage methods MeSH
- Fertility Preservation methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVE: The management and surveillance of glandular pre-cancerous lesions of the uterine cervix present distinct challenges compared with squamous lesions, primarily attributed to the lower effectiveness of diagnostic methods such as cytology or colposcopy. This study aimed to investigate the long-term safety of fertility-sparing treatment for adenocarcinoma in situ and microinvasive adenocarcinoma of the cervix, while identifying factors associated with recurrence, with a particular emphasis on the role of human papillomavirus (HPV) testing. METHODS: We retrospectively reviewed data from all patients with histopathologically confirmed adenocarcinoma in situ or microinvasive cervical adenocarcinoma who received treatment at a single center between 2002 and 2023. The study involved the examination of consecutive surgical specimens and the follow-up details. Factors associated with recurrence were assessed in a subgroup of patients with available long-term follow-up data (at least 6 months). RESULTS: In total, 143 patients (112 with adenocarcinoma in situ and 31 with adenocarcinoma) were included in the analysis. Among the 86 patients who underwent fertility-sparing treatment, the recurrence rate was 9% (12% for adenocarcinoma in situ and 4% for adenocarcinoma) during a median follow-up period of 56.6 months (range 7-179). No patients who were HPV negative experienced recurrence during the follow-up period. In contrast, among patients who were HPV positive, the recurrence rate was 38%. Additionally, HPV 16/18 positivity displayed a notable association with a higher risk of recurrence compared with the other high-risk genotypes, although this difference did not reach statistical significance (83% vs 10%; p=0.083, log-rank). CONCLUSION: Our retrospective study demonstrated a significant association between the risk of recurrence and HPV status during the follow-up period. Consequently, long-term follow-up utilizing HPV testing and genotyping appears to be a secure alternative to a hysterectomy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24020011
- 003
- CZ-PrNML
- 005
- 20241024110924.0
- 007
- ta
- 008
- 241015s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ijgc-2023-004920 $2 doi
- 035 __
- $a (PubMed)38054269
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Dostalek, Lukas $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000301514559
- 245 10
- $a HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix / $c L. Dostalek, P. Freitag, M. Slovackova, T. Zima, M. Komarc, L. Fricova, T. Fucik, K. Nemejcova, D. Cibula, D. Brynda, J. Slama
- 520 9_
- $a OBJECTIVE: The management and surveillance of glandular pre-cancerous lesions of the uterine cervix present distinct challenges compared with squamous lesions, primarily attributed to the lower effectiveness of diagnostic methods such as cytology or colposcopy. This study aimed to investigate the long-term safety of fertility-sparing treatment for adenocarcinoma in situ and microinvasive adenocarcinoma of the cervix, while identifying factors associated with recurrence, with a particular emphasis on the role of human papillomavirus (HPV) testing. METHODS: We retrospectively reviewed data from all patients with histopathologically confirmed adenocarcinoma in situ or microinvasive cervical adenocarcinoma who received treatment at a single center between 2002 and 2023. The study involved the examination of consecutive surgical specimens and the follow-up details. Factors associated with recurrence were assessed in a subgroup of patients with available long-term follow-up data (at least 6 months). RESULTS: In total, 143 patients (112 with adenocarcinoma in situ and 31 with adenocarcinoma) were included in the analysis. Among the 86 patients who underwent fertility-sparing treatment, the recurrence rate was 9% (12% for adenocarcinoma in situ and 4% for adenocarcinoma) during a median follow-up period of 56.6 months (range 7-179). No patients who were HPV negative experienced recurrence during the follow-up period. In contrast, among patients who were HPV positive, the recurrence rate was 38%. Additionally, HPV 16/18 positivity displayed a notable association with a higher risk of recurrence compared with the other high-risk genotypes, although this difference did not reach statistical significance (83% vs 10%; p=0.083, log-rank). CONCLUSION: Our retrospective study demonstrated a significant association between the risk of recurrence and HPV status during the follow-up period. Consequently, long-term follow-up utilizing HPV testing and genotyping appears to be a secure alternative to a hysterectomy.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a nádory děložního čípku $x virologie $x patologie $x diagnóza $x terapie $7 D002583
- 650 12
- $a infekce papilomavirem $x diagnóza $x virologie $7 D030361
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $7 D009364
- 650 _2
- $a zachování plodnosti $x metody $7 D059247
- 650 _2
- $a adenokarcinom $x virologie $x patologie $7 D000230
- 650 _2
- $a třídění pacientů $x metody $7 D014218
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a Papillomaviridae $x izolace a purifikace $7 D027383
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Freitag, Pavel $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Slovackova, Miroslava $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Zima, Tomas $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Komarc, Martin $u Institute of Biophysics and Informatics, First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
- 700 1_
- $a Fricova, Lenka $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Fucik, Tomas $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Nemejcova, Kristyna $u Department of Pathology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Cibula, David $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Brynda, Daniel $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Slama, Jiri $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic Jiri.Slama@vfn.cz
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 34, č. 2 (2024), s. 216-223
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38054269 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024110918 $b ABA008
- 999 __
- $a ok $b bmc $g 2202320 $s 1231984
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 34 $c 2 $d 216-223 $e 20240205 $i 1525-1438 $m International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20241015